{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T07:02:09Z","timestamp":1781938929277,"version":"3.54.5"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,2,4]],"date-time":"2022-02-04T00:00:00Z","timestamp":1643932800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,2,4]],"date-time":"2022-02-04T00:00:00Z","timestamp":1643932800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005090","name":"Beijing Nova Program","doi-asserted-by":"publisher","award":["Z201100006820087"],"award-info":[{"award-number":["Z201100006820087"]}],"id":[{"id":"10.13039\/501100005090","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005088","name":"Beijing Municipal Health Commission","doi-asserted-by":"crossref","award":["2018-1-2061"],"award-info":[{"award-number":["2018-1-2061"]}],"id":[{"id":"10.13039\/501100005088","id-type":"DOI","asserted-by":"crossref"}]},{"name":"the Natural Science Foundation of Beijing, China","award":["7191002"],"award-info":[{"award-number":["7191002"]}]},{"DOI":"10.13039\/501100009601","name":"Beijing Municipal Administration of Hospitals","doi-asserted-by":"publisher","award":["ZYLX201710, DFL20180601"],"award-info":[{"award-number":["ZYLX201710, DFL20180601"]}],"id":[{"id":"10.13039\/501100009601","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009592","name":"Beijing Municipal Science and Technology Commission","doi-asserted-by":"publisher","award":["Z181100001718060"],"award-info":[{"award-number":["Z181100001718060"]}],"id":[{"id":"10.13039\/501100009592","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cardiovasc Disord"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>To study the impact of de-escalation antiplatelet therapy retaining P2Y12 inhibition on major bleeding and ischemic outcomes after percutaneous coronary intervention (PCI) among East Asians and non-East Asians was unclear.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We systematically searched PubMed, Embase, and the Cochrane Library for randomized controlled trials through September 2020. Eight trials were included, which studied de-escalation of DAPT (D-DAPT, switching to P2Y12 inhibitor monotherapy, or switching to clopidogrel or dose reduction of the P2Y12 inhibitor after 1 to 3\u00a0months) versus 12\u00a0months standard DAPT (S-DAPT). The primary outcomes data was conducted using random effects models.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Among the 8 included trials consisting of 37,775 patients, 62.6% presented with acute coronary syndrome. The median follow-up duration ranged from 12 to 24\u00a0months. Compared with S-DAPT, D-DAPT was associated with a lower risk of major bleeding (RR\u2009=\u20090.67, 95% CI 0.48\u20130.93, <jats:italic>p<\/jats:italic>\u2009=\u20090.02); however, this was only observed among East-Asians (RR\u2009=\u20090.61, 95% CI 0.37\u20130.99, <jats:italic>p<\/jats:italic>\u2009=\u20090.048). Among non-East Asians, the rate of major bleeding was similar between the two groups (RR\u2009=\u20090.73, 95% CI 0.46\u20131.14, <jats:italic>p<\/jats:italic>\u2009=\u20090.17, <jats:italic>p<\/jats:italic> for interaction\u2009=\u20090.59). There were no significant differences in the major adverse cardiovascular events (MACE) between D-DAPT and S-DAPT treatment among both East Asians (RR\u2009=\u20090.84, 95% CI 0.66\u20131.08, <jats:italic>p<\/jats:italic>\u2009=\u20090.18) and non-East Asians (RR\u2009=\u20090.89, 95% CI 0.79\u20131.00, <jats:italic>p<\/jats:italic>\u2009=\u20090.059<jats:italic>, p<\/jats:italic> for interaction\u2009=\u20090.71).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The De-escalation strategy that retains P2Y12 inhibition after a PCI was associated with reduced risk of bleeding events, which was only demonstrated in East Asians patients, and not in non-East Asian patients.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12872-022-02476-1","type":"journal-article","created":{"date-parts":[[2022,2,4]],"date-time":"2022-02-04T11:13:54Z","timestamp":1643973234000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["De-escalation of antiplatelet therapy after percutaneous coronary intervention among East Asians and non-East Asians: a meta-analysis of randomized controlled trials"],"prefix":"10.1186","volume":"22","author":[{"given":"Ge","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guanqi","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruifeng","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaoping","family":"Nie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,2,4]]},"reference":[{"key":"2476_CR1","first-page":"1","volume":"00","author":"JP Collet","year":"2020","unstructured":"Collet JP, Thiele H, Barbato E, Barthelemy O, Bauersachs J, Bhatt DL, Dendale P, Dorobantu M, Edvardsen T, Folliguet T, et al. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2020;00:1\u201379.","journal-title":"Eur Heart J"},{"issue":"10","key":"2476_CR2","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1016\/j.jacc.2016.03.513","volume":"68","author":"GN Levine","year":"2016","unstructured":"Levine GN, Bates ER, Bittl JA, Brindis RG, Fihn SD, Fleisher LA, Granger CB, Lange RA, Mack MJ, Mauri L, et al. 2016 ACC\/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2016;68(10):1082\u2013115.","journal-title":"J Am Coll Cardiol"},{"key":"2476_CR3","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1093\/eurheartj\/ehx419","volume":"39","author":"M Valgimigli","year":"2018","unstructured":"Valgimigli M, Byrne RA, Collet J-P, Costa F, Jeppsson A, Juni P. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. Eur Heart J. 2018;39:213\u201354.","journal-title":"Eur Heart J"},{"issue":"5","key":"2476_CR4","first-page":"359","volume":"45","author":"YC Junbo Ge","year":"2017","unstructured":"Junbo Ge YC, et al. Guideline and consensus for the management of patients with non-ST-elevation acute coronary syndrome (2016). Zhonghua Xin Xue Guan Bing Za Zhi. 2017;45(5):359\u201376.","journal-title":"Zhonghua Xin Xue Guan Bing Za Zhi"},{"issue":"10","key":"2476_CR5","first-page":"766","volume":"47","author":"WG Ruiyan Zhang","year":"2019","unstructured":"Ruiyan Zhang WG, et al. 2019 Chinese Society of Cardiology (CSC) guidelines for the diagnosis and management of patients with ST-segment elevation myocardial infarction. Zhonghua Xin Xue Guan Bing Za Zhi. 2019;47(10):766\u201383.","journal-title":"Zhonghua Xin Xue Guan Bing Za Zhi"},{"issue":"9","key":"2476_CR6","first-page":"680","volume":"46","author":"WG Yanling Han","year":"2018","unstructured":"Yanling Han WG, Fu X, et al. Guideline on the diagnosis and treatment of stable coronary artery disease. Zhonghua Xin Xue Guan Bing Za Zhi. 2018;46(9):680\u201394.","journal-title":"Zhonghua Xin Xue Guan Bing Za Zhi"},{"issue":"10257","key":"2476_CR7","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1016\/S0140-6736(20)31791-8","volume":"396","author":"H-S Kim","year":"2020","unstructured":"Kim H-S, Kang J, Hwang D, Han J-K, Yang H-M, Kang H-J, Koo B-K, Rhew JY, Chun K-J, Lim Y-H, et al. Prasugrel-based de-escalation of dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (HOST-REDUCE-POLYTECH-ACS): an open-label, multicentre, non-inferiority randomised trial. The Lancet. 2020;396(10257):1079\u201389.","journal-title":"The Lancet"},{"issue":"24","key":"2476_CR8","doi-asserted-by":"publisher","first-page":"2428","DOI":"10.1001\/jama.2019.8146","volume":"321","author":"JY Hahn","year":"2019","unstructured":"Hahn JY, Song YB, Oh JH, Chun WJ, Park YH, Jang WJ, Im ES, Jeong JO, Cho BR, Oh SK, et al. Effect of P2Y12 inhibitor monotherapy vs dual antiplatelet therapy on cardiovascular events in patients undergoing percutaneous coronary intervention: the SMART-CHOICE randomized clinical trial. JAMA. 2019;321(24):2428\u201337.","journal-title":"JAMA"},{"issue":"23","key":"2476_CR9","doi-asserted-by":"publisher","first-page":"2407","DOI":"10.1001\/jama.2020.7580","volume":"323","author":"BK Kim","year":"2020","unstructured":"Kim BK, Hong SJ, Cho YH, Yun KH, Kim YH, Suh Y, Cho JY, Her AY, Cho S, Jeon DW, et al. Effect of ticagrelor monotherapy vs ticagrelor with aspirin on major bleeding and cardiovascular events in patients with acute coronary syndrome: the TICO randomized clinical trial. JAMA. 2020;323(23):2407\u201316.","journal-title":"JAMA"},{"issue":"24","key":"2476_CR10","doi-asserted-by":"publisher","first-page":"2414","DOI":"10.1001\/jama.2019.8145","volume":"321","author":"H Watanabe","year":"2019","unstructured":"Watanabe H, Domei T, Morimoto T, Natsuaki M, Shiomi H, Toyota T, Ohya M, Suwa S, Takagi K, Nanasato M, et al. Effect of 1-month dual antiplatelet therapy followed by clopidogrel vs 12-month dual antiplatelet therapy on cardiovascular and bleeding events in patients receiving PCI: the STOPDAPT-2 randomized clinical trial. JAMA. 2019;321(24):2414\u201327.","journal-title":"JAMA"},{"issue":"21","key":"2476_CR11","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.1056\/NEJMoa1908419","volume":"381","author":"R Mehran","year":"2019","unstructured":"Mehran R, Baber U, Sharma SK, Cohen DJ, Angiolillo DJ, Briguori C, Cha JY, Collier T, Dangas G, Dudek D, et al. Ticagrelor with or without aspirin in high-risk patients after PCI. N Engl J Med. 2019;381(21):2032\u201342.","journal-title":"N Engl J Med"},{"issue":"10151","key":"2476_CR12","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1016\/S0140-6736(18)31858-0","volume":"392","author":"P Vranckx","year":"2018","unstructured":"Vranckx P, Valgimigli M, J\u00fcni P, Hamm C, Steg PG, Heg D, van Es GA, McFadden EP, Onuma Y, van Meijeren C, et al. Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial. The Lancet. 2018;392(10151):940\u20139.","journal-title":"The Lancet"},{"key":"2476_CR13","doi-asserted-by":"publisher","first-page":"3070","DOI":"10.1093\/eurheartj\/ehx175","volume":"38","author":"T Cuisset","year":"2017","unstructured":"Cuisset T, Quilici J, Johnson TW, Deffarges S, Bassez C, Bonnet G, Fourcade L, Mouret JP, Lambert M, Verdier V, Morange PE, Alessi MC, Bonnet JL. Benefit of switching dual antiplatelet therapy after acute coronary syndrome the TOPIC (timing of platelet inhibition after acute coronary syndrome) randomized study. Eur Heart J. 2017;38:3070\u20138.","journal-title":"Eur Heart J"},{"issue":"10104","key":"2476_CR14","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1016\/S0140-6736(17)32155-4","volume":"390","author":"D Sibbing","year":"2017","unstructured":"Sibbing D, Aradi D, Jacobshagen C, Gross L, Trenk D, Geisler T, Orban M, Hadamitzky M, Merkely B, Kiss RG, et al. Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trial. Lancet. 2017;390(10104):1747\u201357.","journal-title":"Lancet"},{"issue":"1","key":"2476_CR15","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1055\/s-0038-1676545","volume":"119","author":"J Kang","year":"2019","unstructured":"Kang J, Park KW, Palmerini T, Stone GW, Lee MS, Colombo A, Chieffo A, Feres F, Abizaid A, Bhatt DL, et al. Racial differences in ischaemia\/bleeding risk trade-off during anti-platelet therapy: individual patient level landmark meta-analysis from seven RCTs. Thromb Haemost. 2019;119(1):149\u201362.","journal-title":"Thromb Haemost"},{"issue":"6","key":"2476_CR16","doi-asserted-by":"publisher","first-page":"1963","DOI":"10.3390\/jcm9061963","volume":"9","author":"Y Numasawa","year":"2020","unstructured":"Numasawa Y, Sawano M, Fukuoka R, Ejiri K, Kuno T, Shoji S, Kohsaka S. Antithrombotic strategy for patients with acute coronary syndrome: a perspective from East Asia. J Clin Med. 2020;9(6):1963.","journal-title":"J Clin Med"},{"issue":"31","key":"2476_CR17","doi-asserted-by":"publisher","first-page":"2632","DOI":"10.1093\/eurheartj\/ehz372","volume":"40","author":"P Urban","year":"2019","unstructured":"Urban P, Mehran R, Colleran R, Angiolillo DJ, Byrne RA, Capodanno D, Cuisset T, Cutlip D, Eerdmans P, Eikelboom J, et al. Defining high bleeding risk in patients undergoing percutaneous coronary intervention: a consensus document from the Academic Research Consortium for High Bleeding Risk. Eur Heart J. 2019;40(31):2632\u201353.","journal-title":"Eur Heart J"},{"issue":"2","key":"2476_CR18","doi-asserted-by":"publisher","first-page":"194","DOI":"10.3899\/jrheum.121306","volume":"41","author":"EA Ghogomu","year":"2014","unstructured":"Ghogomu EA, Maxwell LJ, Buchbinder R, Rader T, Pardo Pardo J, Johnston RV, Christensen RD, Rutjes AW, Winzenberg TM, Singh JA, et al. Updated method guidelines for cochrane musculoskeletal group systematic reviews and metaanalyses. J Rheumatol. 2014;41(2):194\u2013205.","journal-title":"J Rheumatol"},{"issue":"1","key":"2476_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/2046-4053-4-1","volume":"4","author":"D Moher","year":"2015","unstructured":"Moher D, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart LA. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4(1):1.","journal-title":"Syst Rev"},{"issue":"7","key":"2476_CR20","doi-asserted-by":"publisher","first-page":"537","DOI":"10.4070\/kcj.2018.0166","volume":"48","author":"J Kang","year":"2018","unstructured":"Kang J, Kim HS. The evolving concept of dual antiplatelet therapy after percutaneous coronary intervention: focus on unique feature of East Asian and \u201cAsian Paradox.\u201d Korean Circ J. 2018;48(7):537\u201351.","journal-title":"Korean Circ J"},{"issue":"20","key":"2476_CR21","doi-asserted-by":"publisher","first-page":"3415","DOI":"10.1182\/blood-2013-05-427708","volume":"122","author":"F Samad","year":"2013","unstructured":"Samad F, Ruf W. Inflammation, obesity, and thrombosis. Blood. 2013;122(20):3415\u201322.","journal-title":"Blood"},{"issue":"1","key":"2476_CR22","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1097\/TA.0000000000000490","volume":"78","author":"LZ Kornblith","year":"2015","unstructured":"Kornblith LZ, Howard B, Kunitake R, Redick B, Nelson M, Cohen MJ, Callcut R. Obesity and clotting: body mass index independently contributes to hypercoagulability after injury. J Trauma Acute Care Surg. 2015;78(1):30\u20136 (discussion 37\u201338).","journal-title":"J Trauma Acute Care Surg"},{"issue":"12","key":"2476_CR23","doi-asserted-by":"publisher","first-page":"2629","DOI":"10.1111\/j.1538-7836.2006.02237.x","volume":"4","author":"PL Lutsey","year":"2006","unstructured":"Lutsey PL, Cushman M, Steffen LM, Green D, Barr RG, Herrington D, Ouyang P, Folsom AR. Plasma hemostatic factors and endothelial markers in four racial\/ethnic groups: the MESA study. J Thromb Haemost. 2006;4(12):2629\u201335.","journal-title":"J Thromb Haemost"},{"issue":"2","key":"2476_CR24","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/j.ijcard.2011.11.034","volume":"166","author":"V Veeranna","year":"2013","unstructured":"Veeranna V, Zalawadiya SK, Niraj A, Kumar A, Ference B, Afonso L. Association of novel biomarkers with future cardiovascular events is influenced by ethnicity: results from a multi-ethnic cohort. Int J Cardiol. 2013;166(2):487\u201393.","journal-title":"Int J Cardiol"},{"key":"2476_CR25","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1093\/ehjcvp\/pvaa038","volume":"7","author":"M Bianco","year":"2021","unstructured":"Bianco M, Careggio A, Destefanis P, Luciano A, Perrelli MG, Quadri G, Rossini R, Campo G, Vizzari G, D\u2019Ascenzo F, et al. P2Y12 inhibitors monotherapy after short course of dual antiplatelet therapy in patients undergoing percutaneous coronary intervention: a meta-analysis of randomized clinical trials including 29 089 patients. Eur Heart J Cardiovasc Pharmacother. 2021;7:196\u2013205.","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"issue":"6","key":"2476_CR26","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1161\/CIRCULATIONAHA.120.046251","volume":"142","author":"ML O\u2019Donoghue","year":"2020","unstructured":"O\u2019Donoghue ML, Murphy SA, Sabatine MS. The safety and efficacy of aspirin discontinuation on a background of a P2Y12 inhibitor in patients after percutaneous coronary intervention: a systematic review and meta-analysis. Circulation. 2020;142(6):538\u201345.","journal-title":"Circulation"},{"key":"2476_CR27","doi-asserted-by":"publisher","first-page":"n1332","DOI":"10.1136\/bmj.n1332","volume":"373","author":"M Valgimigli","year":"2021","unstructured":"Valgimigli M, Gragnano F, Branca M, Franzone A, Baber U, Jang Y, Kimura T, Hahn JY, Zhao Q, Windecker S, et al. P2Y12 inhibitor monotherapy or dual antiplatelet therapy after coronary revascularisation: individual patient level meta-analysis of randomised controlled trials. BMJ. 2021;373:n1332.","journal-title":"BMJ"}],"container-title":["BMC Cardiovascular Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-022-02476-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12872-022-02476-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-022-02476-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,4]],"date-time":"2022-02-04T11:17:33Z","timestamp":1643973453000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccardiovascdisord.biomedcentral.com\/articles\/10.1186\/s12872-022-02476-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,4]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["2476"],"URL":"https:\/\/doi.org\/10.1186\/s12872-022-02476-1","relation":{},"ISSN":["1471-2261"],"issn-type":[{"value":"1471-2261","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,4]]},"assertion":[{"value":"12 July 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 January 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"29"}}